PMC:7594251 / 38215-38378 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T21500","span":{"begin":123,"end":130},"obj":"Body_part"}],"attributes":[{"id":"A1423","pred":"fma_id","subj":"T21500","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":"This has been done mainly via the Fragment Based Drug Design (FBDD) approach, which has two sub-approaches: target- (i.e., protein) based, or ligand- (drug) based."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T279","span":{"begin":5,"end":8},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T280","span":{"begin":84,"end":87},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"}],"text":"This has been done mainly via the Fragment Based Drug Design (FBDD) approach, which has two sub-approaches: target- (i.e., protein) based, or ligand- (drug) based."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T383","span":{"begin":123,"end":130},"obj":"Chemical"},{"id":"T384","span":{"begin":142,"end":148},"obj":"Chemical"},{"id":"T385","span":{"begin":151,"end":155},"obj":"Chemical"}],"attributes":[{"id":"A383","pred":"chebi_id","subj":"T383","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A384","pred":"chebi_id","subj":"T384","obj":"http://purl.obolibrary.org/obo/CHEBI_52214"},{"id":"A385","pred":"chebi_id","subj":"T385","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"}],"text":"This has been done mainly via the Fragment Based Drug Design (FBDD) approach, which has two sub-approaches: target- (i.e., protein) based, or ligand- (drug) based."}

{"project":"LitCovid-sentences","denotations":[{"id":"T265","span":{"begin":0,"end":163},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"This has been done mainly via the Fragment Based Drug Design (FBDD) approach, which has two sub-approaches: target- (i.e., protein) based, or ligand- (drug) based."}